Mesoblast Reports Strong Growth in Ryoncil Sales and Expands Global Reach

Mesoblast Limited (ASX: MSB), a biotechnology company specializing in allogeneic cellular medicines for inflammatory diseases, reported a 66% quarter-on-quarter increase in Ryoncil® (remestemcel-L-rknd) revenues, reaching US$21.9 million for the quarter ended September 30, 2025. Ryoncil® has earned distinction as the first U.S. FDA-approved mesenchymal stromal cell (MSC) therapy, developed to help children below 12 years of age who do not respond to steroid treatment for acute graft-versus-host disease (SR-aGvHD). CEO Dr. Silviu Itescu credited the rise to broader adoption and reimbursement support, noting further growth expected after CMS granted a permanent J-Code. Mesoblast is advancing its innovative cell therapy platforms, remestemcel-L and rexlemestrocel-L, to address a range of conditions including adult steroid-refractory graft-versus-host disease, inflammatory bowel disease resistant to biologics, chronic heart failure, and persistent lower back pain. With over 1,000 patents ensuring protection through 2041, and manufacturing hubs in Australia, the U.S., and Singapore, the company is positioned for sustained expansion across global healthcare markets.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com